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Abstract
OBJECTIVE: To assess the therapeutic effect of
weekend fasting and administration of a modified
Lingguizhugan decoction on metabolic syndrome
(MetS).
METHODS: Twenty-one patients with MetS were
recruited from the First Affiliated Hospital of Sun
Yat-Sen University. Fasting plasma glucose (FPG),
30-min and 2-h post-prandial blood glucose (PG),
fasting serum insulin (FINS), blood pressure (BP),
body mass index (BMI), waist circumference (WC),
homeostasis model assessment for insulin resis-
tance index (HOMA-IR), and levels of triglyceride
(TG), total cholesterol (TC), low-density lipopro-
tein-cholesterol (LDL-C), and high-density lipopro-
tein cholesterol (HDL-C) were tested. Patients were
allowed to drink only water and a Chinese herbal
decoction during weekends. All samples were test-
ed again after 12 weeks of treatment.
RESULTS: FPG, 30-min PG, 2-h PG, FINS, LDL-C, sys-
tolic BP, diastolic BP, BMI, WC, and HOMA-IR de-
creased significantly (P<0.05) compared with be-
fore treatment. Levels of TG, TC, and HDL-C did not
change significantly.
CONCLUSION: Weekend fasting improved glucose
metabolism, lowered BP, reduced LDL-C levels, BMI,
and WC. These data suggest that weekend fasting
may be an effective therapy for MetS by protection
against coronary atherosclerosis.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Metabolic syndrome (MetS) is a multifactorial disorder
that comprises obesity, hypertension, impaired glucose
tolerance, and low levels of high-density lipoprotein
cholesterol (HDL-C).1-3 Suffering from MetS can mean
a fivefold and twofold increased risk of developing
type-2 diabetes mellitus (T2DM) and cardiovascular
disease (CVD), respectively.4-6
Since 2011, our research team has used fasting therapy
as a new approach to treat obesity, hyperlipidemia,
T2DM, impaired glucose tolerance, and hypertension.
The aim of the present study was to explore the clinical
evidence of weekend fasting therapy on the MetS.
MATERIALS ANDMETHODS
Subjects
Twenty-one subjects (12 males and 9 females; 30-65
years) were recruited from the First Affiliated Hospital
of Sun Yat-Sen University from January 2011 to Janu-
ary 2013. Patients were required to suspend any medi-
cation for a minimum of 7 daysbeforebeginning therapy.
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The inclusion criterion was that subjects had to be
aged between 17 and 70 years. This study was ap-
proved by the Ethics Committee of the First Affiliated
Hospital of Sun Yat-Sen University (Guangzhou, Chi-
na). All subjects provided written informed consent to
be included in the study.
Patients were excluded if they: (a) had a history of gas-
tric ulcers, anorexia, T2DM, coronary artery disease,
cancer, stroke, or any other serious chronic infection;
(b) were having complications after malnutrition or
psychiatric disorders, or if they were post-menopausal;
(c) had a history of using any medication affecting lip-
id metabolism, body weight or energy metabolism; (d)
had a history of using tobacco, excessive use of alcohol,
or had abused other substances. Pregnant women,
breastfeeding women, and those who planned to be-
come pregnant within the following year were also ex-
cluded.
Diagnostic standards
Cutoff values for body mass index (BMI), waist circum-
ference (WC), total cholesterol (TC), fasting plasma
glucose (FPG), blood pressure (BP), triglycerides (TG)
and high-density lipoprotein-cholesterol (HDL-C)
were established according to the United States Nation-
al Cholesterol Education Program Expert Panel on De-
tection, Evaluation, and Treatment of High Blood Cho-
lesterol in Adults (Adult Treatment PanelⅢ)7 (Table 1).
Methods
Physical examination and blood tests were conducted
before treatment to establish baseline values, and all
items were tested again after 12 weeks. Physical exami-
nation included evaluation of body weight (BW) and
WC. Specifically, WC was measured at the highest lev-
el of the iliac crest using an elastic band meter. Blood
tests included evaluation of TC, TG, LDL-C, HDL-C,
FPG, 30-min post-prandial blood glucose (PG), 2-h
PG, and fasting serum insulin (FINS). Briefly, all sub-
jects received training regarding the treatment process
and possible side effects. The day before the beginning
of therapy, patients were asked to control food intake
(especially limiting the amount of meat and increasing
the amount of vegetables that they consumed). On the
first day of treatment (Saturday), they were shown how
to dissolve 30 g of Xuanmingfen (Natrii Sulfas Exsicca-
tus) in 300-400 mL of water and instructed to drink
the solution in 10 min. Then, they had to drink a mod-
ified Lingguizhugan decoction (200 mL) twice a day.
The modified Lingguizhugan decoction comprised
Chinese herbal medicines such as Dangshen (Radix Co-
donopsis) 20 g, Guizhi (Ramulus Cinnamomi) 12 g, Ful-
ing (Poria) 30 g, Baizhu (Rhizoma Atractylodis Macro-
cephalae) 15 g, Gancao (Radix Glycyrrhizae) 6 g; Da-
huang (Radix Et Rhizoma Rhei Palmati) 9 g. One dose
was decocted and taken twice a day. All herbs were pro-
vided by Kang Mei Pharmaceutical Co, Ltd. (Puning,
Guangdong, China). Patients were required to drink ≥
3000 mL of mineral water per day. Moderate exercise
was needed for ≥1 h per day. This treatment was the
same for the second day (Sunday). For the following 5
days after the weekend of fasting, subjects had to
change their diet gradually from fluid to solid food. Ex-
ercise levels remained the same. This protocol had to
be followed every other week, and a total course of
treatment lasted for 12 weeks.
Possible side effects included dizziness and weakness
due to hypoglycemia. Patients were advised to eat a
small piece of candy or chocolate if hypoglycemia oc-
curred during treatment. If low BP occurred three
times per day or even continued after food intake, treat-
ment was suspended. Patients were advised to measure
their BP if they felt dizzy or weak. If their BP was ab-
normal, they had to stop therapy and contact the at-
tending physician immediately. Extensive exercise and
heavy labor had to be avoided during therapy. Howev-
er, mild exercise such as walking, jogging, or tai chi
was allowed.
Statistical analyses
Data are the mean±standard deviation. Data were eval-
uated using SPSS version 16.0 (SPSS, Chicago, IL,
USA). Data collected before and after treatment were
compared by RANOVA. P<0.05 was considered sig-
nificant.
RESULTS
Adverse effects
The main adverse effects were hypoglycemia (1 pa-
Risk factor
Waist circumference (cm)
Triglycerides (mg/dL)
High-density lipoprotein-cholesterol (mg/dL)
Blood pressure (mm Hg)
Fasting glucose (mg/dL)
Gender
Male
Female
Male
Female
Defining level
>102
>88
≥150
<40
<50
≥130/≥85
≥110
Table 1 Clinical identification of MetS
Note: MetS: metabolic syndrome.
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tient), as well as mild dizziness and fatigue (80% of pa-
tients). Normal glucose levels were re-established by
consuming chocolate.
Physical examination
Levels of BW, WC, BMI, systolic BP (SBP), and dia-
stolic BP (DBP) were decreased after 12 weeks of treat-
ment. All changes were significant compared with
those before treatment (all P<0.05) (Table 2).
Blood tests
Levels of TC, TG, LDL-C, HDL-C, OGTT, FINS,
and HOMA-IR were siginificantly changed after 12
weeks of treatment, in which TC, TG, LDL-C,
OGTT, FINS, and HOMA-IR were all decreased,
while HDL-C increased (all P<0.05) (Table 3).
DISCUSSION
MetS is a well-known cluster of multiple metabolic ab-
normalities (obesity, insulin resistance, hypertension,
dyslipidemia and high BP) and a major risk factor for
CVD.8-10 Usually, the MetS is treated by maintaining
body weight, the BMI, blood parameters, and BP with-
in normal levels, so patients receive several medications
simultaneously. A faster lifestyle with less exercise and
more time spent at home may (at least in part) explain
the high prevalence of the MetS in China.11
Several studies have shown that the development of
MetS is caused by an unhealthy lifestyle and by exces-
sive intake of food.12,13 However, sometimes, genetic fac-
tors can also play a part.14,15 Leading health authorities
have recommended lifestyle adjustments as treatment
for prevention of MetS. These authorities have also sug-
gested increased exercise and calorie restriction. Such
lifestyle modifications has been shown to improve all
components of MetS.16
Abdominal obesity or visceral adiposity are hallmarks
of MetS. These hallmarks have been shown to be close-
ly associated with insulin resistance, dyslipidemia, hy-
perinsulinemia, and hypertension.17,18 Moreover, WC
has been shown to be reduced through physical activity
and overall reduction of weight.19
Results from the present study demonstrated that thera-
py based upon weekend fasting reduced the BMI and
visceral fat of the study cohort. In particular, after
weekend fasting, visceral adiposity was reduced consid-
erably. Moreover, it has been reported that abdominal
adiposity is a major contributor to the development of
insulin resistance and hyperglycemia.20 Reduction of
the BMI and WC in the fasting group suggested that
weekend-fasting therapy could help to prevent insulin
resistance and MetS. Data from our study also demon-
strated that weekend fasting regulated SBP and DBP
to normal levels in MetS patients. A Japanese study (to-
tal cohort of 2985 adults) showed that hypertension is
one of the most common components (57.8% ) of
MetS.21 In this respect our results suggest that this treat-
ment could be used to prevent hypertension in MetS
patients.
In addition, our results showed that weekend-fasting
therapy had a effect of lowering the LDL-C level,
which is a classic risk factor for atherosclerosis.22 How-
ever, weekend fasting showed no effects on levels of
TG, TC, and HDL-C, and further studies. In one
study, the risk of suffering from T2DM increased by
5-9-fold in MetS patients.23 Here, we demonstrated
that weekend fasting improved the outcome of the oral
glucose tolerance test and regulated dysfunctional glu-
cose metabolism. Finally, it has been shown that viscer-
al fat is closely associated with inflammation and insu-
lin resistance because of the numerous immune modu-
latory factors secreted from adipose tissue.24 We specu-
late that fasting therapy could decrease blood glucose
Time
Pre-treatment
Post-treatment
BW (kg)
72±6
62±6
WC (cm)
92±8
87±7
BMI (kg/m2)
32±3
28±3
SBP (mm Hg)
144±8
138±7
DBP (mm Hg)
96±6
86±5
Notes: BW: body weight; WC: waist circumference; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 2 Comparison of body weight, WC, BMI, SBP, and DBP in 21 cases ( xˉ ±s)
Time
Pre-treatment
Post-treatment
TC (mmol/L)
6.4±0.8
6.3±0.8a
TG (mmol/L)
2.9±0.8
2.6±0.4a
LDL-C (mmol/L)
4.2±1.1
2.5±1.0b
HDL-C (mmol/L)
1.2±0.5
1.3±0.6a
Table 3 Comparison of levels of TC, TG, LDL-C, HDL-C, OGTT, FINS, and HOMA-IR in 21 cases ( xˉ ±s)
Time
Pre-treatment
Post-treatment
FPG (mmol/L)
7.13±0.36
4.86±0.24b
30-min PG (mmol/L)
13.41±1.02
9.58±0.76b
2-h PG (mmol/L)
8.97±0.54
7.14±0.69b
FINS (mU/mL)
13.53±0.36
10.71±0.28b
HOMA-IR
3.27±0.21
2.05±0.18b
Notes: TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol;
FGP: fasting plasma glucose; 30-min PG: 30-min post-prandial blood glucose; 2-h PG: 2-h post-prandial blood glucose; FINS: fasting se-
rum insulin; HOMA-IR: homeostasis model assessment for insulin resistance index. aP>0.05, compared with pre-treatment; bP<0.05, com-
pared with pre-treatment.
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content by down-regulation of secretion of the inflam-
matory and immunomodulatory factors associated
with the reduction of visceral fat. Excess body fat (an
important risk for the MetS and CVD), also results in
inflammatory conditions. Some studies have shown
that increased levels of inflammatory cytokines such as
C-reactive protein, interleukin-6 and tumor necrosis
factor-α produced by adipocytes may be related to en-
hanced infiltration of inflammatory cells within adi-
pose tissue.25,26
Lingguizhugan decoction combined with weekend fast-
ing improved glucose metabolism, lowered BP, and de-
creased LDL-C levels, the BMI, and WC. This combi-
nation could be a potential treatment of the MetS by
reducing adipose tissue (especially visceral fat) and pro-
tect patients from coronary atherosclerosis. We suggest
that the reduction of levels of inflammatory cytokines
secreted from adipose tissue might be the key mecha-
nism involved in this process.
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